Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19

The SARS-CoV-2 3CL protease is a critical drug target for small molecule COVID-19 therapy, given its likely druggability and essentiality in the viral maturation and replication cycle. Based on the conservation of 3CL protease substrate binding pockets across coronaviruses and using screening, we id...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hengrui, Iketani, Sho, Zask, Arie, Khanizeman, Nisha, Bednarova, Eva, Forouhar, Farhad, Fowler, Brandon, Hong, Seo Jung, Mohri, Hiroshi, Nair, Manoj S., Huang, Yaoxing, Tay, Nicholas E. S., Lee, Sumin, Karan, Charles, Resnick, Samuel J., Quinn, Colette, Li, Wenjing, Shion, Henry, Xia, Xin, Daniels, Jacob D., Bartolo-Cruz, Michelle, Farina, Marcelo, Rajbhandari, Presha, Jurtschenko, Christopher, Lauber, Matthew A., McDonald, Thomas, Stokes, Michael E., Hurst, Brett L., Rovis, Tomislav, Chavez, Alejandro, Ho, David D., Stockwell, Brent R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989888/
https://www.ncbi.nlm.nih.gov/pubmed/35393402
http://dx.doi.org/10.1038/s41467-022-29413-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989888/
https://www.ncbi.nlm.nih.gov/pubmed/35393402
http://dx.doi.org/10.1038/s41467-022-29413-2

Ejemplares similares